HomeNewsBusinessCompaniesCoronavirus pandemic | Life insurers race against time to meet sales targets
Trending Topics

Coronavirus pandemic | Life insurers race against time to meet sales targets

Lockdown due to COVID-19 has kept customers away from bank branches while agents are also unable to make sales visits due to suspension of public transport across the country.

March 31, 2020 / 15:22 IST
Story continues below Advertisement

At a Mumbai-based life insurance company, only 30 percent of its 8,000 strong work-force has been reporting to work for the past 10 days. March is a busy period for the companies because it is not just the end of the financial year but also a period which accounts for a large proportion of their yearly sales by salaried professionals.

“New policy sales have been low. Since the government has allowed individuals time till June 30 to make investments for tax-saving purposes, the traction is slow. At out bank branches too, there is hardly anyone walking in,” said the senior vice president of the company.

Story continues below Advertisement

For life insurers, bank branches are the top source of business. Be it from a new policy perspective or from a premium perspective. Bank customers are considered savvier when it comes to investment products of insurers. Hence the average ticket size of bank-led insurers is at least 10-15 percent higher than that of the counterparts.

In a decade, the share of banks in private life insurance distribution has seen an almost 100 percent jump, from 25 percent in 2008-09 to touch 50 percent at the end of 2019.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show